|
Indications and Dosage
Oral
Gastric and duodenal ulcers Adult: 400 mg bid for 4-8 wk. Oral Benign gastric ulcer Adult: 400 mg bid for 8 wk. Oral Eradication of Helicobacter pylori associated with peptic ulcer disease Adult: As triple therapy (ranitidine bismuth citrate 400 mg, clarithromycin 500 mg and amoxicillin 1000 mg): Taken bid for 7 days.
|
|
Administration
Should be taken with food. Swallow whole, do not chew/crush.
|
|
Contraindications
Moderate to severe renal impairment.
|
|
Special Precautions
Exclude malignancy prior to therapy. Renal impairment. Elderly, childn. Pregnancy and lactation.
|
|
Adverse Reactions
Blackening of tongue and stools; GI upset, headache, mild anaemia, bradycardia, altered liver enzymes. Rarely, hypersensitivity, confusion, hepatitis, pancreatitis, blood dyscrasias, musculoskeletal disorders, male breast symptoms.
|
|
Action
Description:
Mechanism of Action: Ranitidine bismuth citrate dissociates in the stomach and releases ranitidine and bismuth. It provides a unique combination of properties including inhibition of secretion of gastric acid by competitive antagonism of the action of histamine at the histamine H2-receptor on the gastric parietal cell, mucosal protective effects and anti-H. pylori action. |
|
Chemical Structure
 Source: National Center for Biotechnology Information. PubChem Database. Ranitidine bismuth citrate, CID=3033887, https://pubchem.ncbi.nlm.nih.gov/compound/Ranitidine-bismuth-citrate (accessed on Jan. 22, 2020) |
|
MIMS Class
|
|
References
Buckingham R (ed). Ranitidine Bismuth Citrate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 17/06/2015.
|
Sign Out
